PMID- 33979868
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1439-0795 (Electronic)
IS  - 0176-3679 (Linking)
VI  - 54
IP  - 4
DP  - 2021 Jul
TI  - The Potential Role of Psychedelic Drugs in Mental Health Care of the Future.
PG  - 191-199
LID - 10.1055/a-1486-7386 [doi]
AB  - Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), 
      or dimethyltryptamine (DMT), as well as psychoactive drugs that trigger 
      phenomenologically- related experiences like 3,4-methylenedioxymethamphetamine 
      (MDMA) and ketamine, belong to the most promising treatment approaches in 
      contemporary psychiatry. Psychedelic-assisted psychotherapy is not only a new 
      treatment paradigm in psychopharmacology, but it also requires a redefinition of 
      psychotherapeutic processes and the contextualization of psychopharmacological 
      interventions within a new treatment infrastructure. Crucial for future practice 
      and research in the field are (1) informed patient referral and co-treatment 
      practices, (2) screening (e. g., choosing the right patients for these 
      therapies), (3) the dosing preparation sessions, (4) the assisted dosing sessions 
      as well as after-care procedures such as (5) psychological integration and (6) 
      supporting the development of structured patient communities. Definition of 
      future treatment delivery infrastructures and requirements for therapist training 
      are further challenges for research and practice. Finally, the implementation of 
      psychedelic-assisted psychotherapy in routine mental health care must be embedded 
      into public communication about the potential and risks of these innovative 
      therapeutic approaches. This paper provides a synopsis of challenges for 
      practitioners, researchers, and regulators to be addressed in the approval 
      processes of psychedelics.
CI  - Thieme. All rights reserved.
FAU - Grunder, Gerhard
AU  - Grunder G
AUID- ORCID: 0000-0001-7868-3903
AD  - Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical 
      Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
AD  - OVID Health Systems GmbH, Berlin, Germany.
FAU - Jungaberle, Henrik
AU  - Jungaberle H
AUID- ORCID: 0000-0001-7634-4211
AD  - OVID Health Systems GmbH, Berlin, Germany.
AD  - MIND Foundation gGmbH, Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210512
PL  - Germany
TA  - Pharmacopsychiatry
JT  - Pharmacopsychiatry
JID - 8402938
RN  - 0 (Hallucinogens)
RN  - 0 (Pharmaceutical Preparations)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
SB  - IM
MH  - *Hallucinogens/therapeutic use
MH  - Humans
MH  - Lysergic Acid Diethylamide
MH  - Mental Health
MH  - *Pharmaceutical Preparations
MH  - Psilocybin/therapeutic use
COIS- Drs. Grunder and Jungaberle are founders and CEOs of OVID Health Systems, Berlin. 
      Dr. Jungaberle is founder and CEO of the MIND Foundation, Berlin. Dr. Grunder is 
      chairman of the Advisory Board of the MIND Foundation. In addition, Dr. Grunder 
      has served as consultant and advisory board member during the last three years 
      for the following companies and institutions: Allergan, Boehringer Ingelheim, 
      IQWiG, Lundbeck, Otsuka, Recordati, ROVI and Takeda. He has received honoraria as 
      a speaker for Gedeon-Richter, Janssen-Cilag, Lundbeck, Otsuka and Recordati. He 
      has received funding for clinical trials from Boehringer Ingelheim, Lundbeck and 
      Saladax. He is the co-founder of Brainfoods GmbH and Mind and Brain Institute 
      GmbH.
EDAT- 2021/05/13 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/05/12 20:19
PHST- 2021/05/13 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2021/05/12 20:19 [entrez]
AID - 10.1055/a-1486-7386 [doi]
PST - ppublish
SO  - Pharmacopsychiatry. 2021 Jul;54(4):191-199. doi: 10.1055/a-1486-7386. Epub 2021 
      May 12.